MedTrace Logo

Liposome Bupivacaine for WRIST Blocks

NCT03106519 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2020-09-10

No results posted yet for this study

Summary

Treatment of Dupuytren's contracture requires multiple injections into the palm of the hand to weaken the cords, followed by rupture of the strands 2 days later. Anesthesia is required for both phases of treatment. It is hypothesized that extended-release liposome bupivacaine prolongs nerve blockade of the wrist allowing patients to undergo this 2-part regimen with less pain.

Conditions

  • Dupuytren's Contracture of the Hand (Viking's Disease)

Interventions

DRUG

Liposome bupivacaine + bupivacaine

Sponsors & Collaborators

  • Pacira Pharmaceuticals, Inc

    collaborator INDUSTRY

  • Catherine Vandepitte, M.D.

    lead OTHER

Principal Investigators

  • Admir Hadzic, MD, PhD · Ziekenhuis Oost-Limburg

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-02
Primary Completion
2017-06-28
Completion
2017-10-31
FDA Drug
Yes

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03106519 on ClinicalTrials.gov